Rotavirus vaccine RIX4414 (Rotarix™)

Pediatric Drugs

Volumn 8, Issue 6, 2006, Pages 389-395

  Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; NEISSERIA MENINGITIDIS VACCINE; ORAL POLIOMYELITIS VACCINE; PLACEBO; RIX 4414; ROTAVIRUS VACCINE; VIRUS ANTIGEN;

ANOREXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DIPHTHERIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; GASTROENTERITIS; HEPATITIS B; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INTUSSUSCEPTION; IRRITABILITY; META ANALYSIS; NAUSEA; NEISSERIACEAE INFECTION; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINORRHEA; RISK FACTOR; SEROCONVERSION; SEROTYPE; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; TETANUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

CLINICAL TRIALS; DRUG TOLERANCE; HUMANS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 33845473656     PISSN: 11745878     EISSN: 11745878     Source Type: Journal    
DOI: 10.2165/00148581-200608060-00006     Document Type: Review

References (26)

1. Sabin Vaccine Institute. Proceedings of the Sixth International Rotavirus Symposium; 2004 Jul 7-9; Mexico City [online]. Available from URL: http://www.sabin.org/PDF/rotavirusengweb.pdf [Accessed 2005 Jun 10]
2. Widdowson M-A, Bresee JS, Gentsch JR, et al. Rotavirus disease and its prevention. Curr Opin Gastroenterol 2005; 21: 26-31
3. Soriano-Gabarró M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006 Jan; 25 (1 Suppl.): S7-11
4. Glass RI, Bresee JS, Parashar UD, et al. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004 May 8; 363 (9420): 1547-50
5. De Vos B, Vesikari T, Linhares AC, et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 2004 Oct; 23 (10 Suppl.): S179-82
6. GlaxoSmithKline. Rotarix: first vaccine against rotavirus available in Europe [media release]. Available from URL: http://www.gsk.com [Accessed 2006 Mar 8]
7. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998 Feb; 16 (4): 381-7
8. Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999 Jul 24; 354 (9174): 287-90
9. Bernstein DI, Sack DA, Reisinger K, et al. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002 Nov 15; 186: 1487-9
10. European Medicines Agency. Rotarix: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2006 Sep 13]
11. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004 Jul 29; 22: 2836-42
12. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004 Oct; 23 (10): 937-43
13. Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 2005 Jun; 24 (6): 481-8
14. Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis 2005 Sep 1; 192 Suppl. 1: S6-16
15. Salinas B, Pérez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005 Sep; 24 (9): 807-16
16. Steele AD, Tumbo JM, Armah GE, et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants [abstract]. 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases; 2005 May 18-20; Valencia
17. Vesikari T, Karvonen A, Prymula R, et al. Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries [abstract]. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2006 May 3-5; Basel
18. Schuster V, Otto W, Cohen R, et al. Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (Prevenar™) in healthy infants from France and Germany [abstract]. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2006 May 3-5; Basel
19. Tejedor JC, Díez-Delgado J, Arístegui J, et al. Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitidis serogroup C vaccine (Meningitec™) in healthy infants from Spain [abstract]. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2006 May 3-5; Basel
20. Vesikari T, Prymula R, Schuster V, et al. Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphtheria-tetanus-pertussis (DTPa)-combined vaccines in healthy infants from Europe [abstract]. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2006 May 3-5; Basel
21. European Medicines Agency. Rotarix: scientific discussion [online]. Available from URL: http://www.emea.eu.int [Accessed 2006 Sep 15]
22. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006 Jan 5; 354 (1): 11-22
23. Vesikari T, Karvonen A, Prymula R, et al. Human rotavirus vaccine Rotarix™ (RIX4414) is highly efficacious in Europe [abstract]. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2006 May 3-5; Basel
24. Vesikari T, Prymula R, Schuster V, et al. Early protection against rotavirus, Rotarix™ (RIX4414) experience in a European setting [abstract no. 68.021]. Int J Infect Dis 2006 Jun; 10 Suppl. 1: 324
25. Perez-Schael I, Linhares AC, Vesikari T, et al. Two doses of the human-attenuated rotovirus vaccine RIX4414 show heterotypic protection in Latin America and Europe [abstract no. LB-12]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington, DC
26. De Vos B, Gillard P, Cheuvart B, et al. RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain [abstract no. G-618]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)